Perspectives in the Design of Peptide Analogues in Biomedical Applications
Author:
St-Pierre Serge A.
Reference39 articles.
1. Banks, W. A., Kastin, A. J., and Coy, D. H., 1984, Evidence that [125I]N-Tyr-delta sleep-inducing peptide crosses the blood-brain barrier by a noncompetitive mechanism, Brain Res. 301:201–207. 2. Bhatnagar, P. K., Papas, E., Blum, H. E., Milich, D. R., Nitecki, D., Karels, M. J., and Vyas, G. N., 1982, Immune response to synthetic peptide analogues of hepatitis B surface antigen for the a determinant, Proc. Natl. Acad. Sci. U.S.A. 79:4400–4404. 3. Biddle, J. L., Houghten, R. A., Alexander, H., Shinnick, T. M., Sutcliff, J. G., Lerner, R. A., Rowlands, D. J., and Brown, F., 1982, Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence, Nature 298:30–33. 4. Blake, J., Ferrara, P., and Li, C. H., 1981, Beta-endorphin: Synthesis and radioligand binding activity of analogs containing cystine bridges, Int. J. Peptide Protein Res. 17:239–242. 5. Blanc, J. P., and Kaiser, E. T., 1984, Biological and physical properties of a beta-endorphin analog containing only D-amino acids in the amphiphilic helical segment 13-31, J. Biol. Chem. 259:9549–9556.
|
|